Tuesday October 23, 2018

Omega-3 Fatty Acids in Diet can Prevent Cancer From Spreading

While dietary consumption of omega-3 fatty acids can lead to EDP-EAs, for those with cancer, something concentrated and fast acting is needed

0
//
27
Eating more ALA -- an essential fatty acid and important part of a balanced diet -- through food or supplements probably decreases the risk of heart irregularities from 3.3 to 2.6 per cent.
Eating more ALA -- an essential fatty acid and important part of a balanced diet -- through food or supplements probably decreases the risk of heart irregularities from 3.3 to 2.6 per cent. (IANS)
Republish
Reprint

While eating foods rich in omega-3 fatty acids, such as fatty fish, certain nuts and seeds, have been known to prevent heart diseases and arthritis, a new research, led by one of Indian-origin, showed that omega-3 fatty byproducts may also have anti-cancer effects.

The new study, led by Aditi Das from University of Illinois at Urbana-Champaign, US, showed that when the human body metabolises omega-3 fatty acids, it produces a class of molecules called endocannabinoid epoxides, or EDP-EAs. These have anti-inflammatory properties and can inhibit cancer’s growth and spread.

The EDP-EAs have similar properties to cannabinoids found in marijuana — but without the psychotropic effects — and they target the same receptor in the body that cannabis does.

“We have a built-in endocannabinoid system which is anti-inflammatory and pain-reducing. Now we see it is also anti-cancer, stopping the cells from proliferating or migrating,” said study leader Aditi Das from University of Illinois at Urbana-Champaign.

The higher concentrations of EDP-EAs did kill cancer cells, but not as effectively as other chemotherapeutic drugs on the market.
The higher concentrations of EDP-EAs did kill cancer cells, but not as effectively as other chemotherapeutic drugs on the market. Pixabay

“These molecules could address multiple problems: cancer, inflammation and pain,” Das added.

For the study, published in the Journal of Medicinal Chemistry, the team studied the effect of the molecule in mice with tumours of osteosarcoma — a bone cancer that is not only painful but also difficult to treat.

The results showed that the endocannabinoids slowed the growth of tumours and blood vessels, inhibited the cancer cells from migrating and caused cancer cell death.

The higher concentrations of EDP-EAs did kill cancer cells, but not as effectively as other chemotherapeutic drugs on the market. But, the compounds slowed tumour growth by inhibiting new blood vessels from forming to supply the tumour with nutrients. They also prevented interactions between the cells, and most significantly, they appeared to stop cancerous cells from migrating.

Also Read: Cancer-Causing Chemical Found In Odisha Fish Sample

While dietary consumption of omega-3 fatty acids can lead to EDP-EAs, for those with cancer, something concentrated and fast acting is needed, Das said.

“That’s where the endocannabinoid epoxide derivatives come into play – you could make a concentrated dose of the exact compound that’s most effective against the cancer. You could also mix this with other drugs such as chemotherapies,” she added. (IANS)

Click here for reuse options!
Copyright 2018 NewsGram

Next Story

Immunotherapy Drugs Show Significant Improvement Against Breast Cancer: Study

Side effects need a close look, both doctors said. Nearly all study participants had typical chemo side effects such as nausea or low blood cell counts.

0
Breast Cancer
This undated fluorescence-colored microscope image made available by the National Institutes of Health in September 2016 shows a culture of human breast cancer cells. For the first time, one of the new immunotherapy drugs has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease. VOA

For the first time, one of the new immunotherapy drugs has shown promise against breast cancer in a large study that combined it with chemotherapy to treat an aggressive form of the disease. But the benefit for most women was small, raising questions about whether the treatment is worth its high cost and side effects.

Results were discussed Saturday at a cancer conference in Munich and published by the New England Journal of Medicine.

Drugs called checkpoint inhibitors have transformed treatment of many types of cancer by removing a chemical brake that keeps the immune system from killing tumor cells. Their discovery recently earned scientists a Nobel Prize. Until now, though, they haven’t proved valuable against breast cancer.

Breast Cancer
Weight loss may lower breast cancer risk for post-menopausal women. Pixabay

In the study

The new study tested one from Roche called Tecentriq plus chemo versus chemo alone in 902 women with advanced triple-negative breast cancer. About 15 percent of cases are this type, their growth is not fueled by the hormones estrogen or progesterone, or the gene that Herceptin targets, making them hard to treat.

Women in the study who received Tecentriq plus chemo went two months longer on average without their cancer worsening compared with those on chemo alone, a modest benefit. The combo did not significantly improve survival in an early look before long-term follow-up is complete.

Failed protein test

Previous studies found that immunotherapies work best in patients with high levels of a protein that the drugs target, and the plan for the breast cancer study called for analyzing how women fared according to that factor if Tecentriq improved survival overall.

breast cancer
FILE – A patient receives chemotherapy treatment for breast cancer at the Antoine-Lacassagne Cancer Center in Nice, July 26, 2012. VOA

The drug failed that test, but researchers still looked at protein-level results and saw encouraging signs. Women with high levels who received the combo treatment lived roughly 25 months on average versus about 15 months for women given chemo alone.

That’s a big difference, but it will take more time to see if there’s a reliable way to predict benefit, said Dr. Jennifer Litton of the MD Anderson Cancer Center in Houston. She had no role in running the study but enrolled some patients in it and oversees 14 others testing immunotherapies.

“We’re really hopeful that we can identify a group of women who can get a much bigger and longer response,” she said.

Another breast cancer specialist with no role in the study, Dr. Michael Hassett at Dana-Farber Cancer Institute in Boston, said he felt “cautious excitement” that immunotherapy may prove helpful for certain breast cancer patients.

Breast Cancer
Breast cancer cell, Wikimedia Commons

Side effects and cost

Side effects need a close look, both doctors said. Nearly all study participants had typical chemo side effects such as nausea or low blood cell counts, but serious ones were more common with the combo treatment and twice as many women on it stopped treatment for that reason.

Three of the six deaths from side effects in the combo group were blamed on the treatment itself; only one of three such deaths in the chemo group was.

Also Read: New DNA Tool To Predict People’s Height And Risk For Cancer

Cost is another concern. Tecentriq is $12,500 a month. The chemo in this study was Celgene’s Abraxane, which costs about $3,000 per dose plus doctor fees for the IV treatments. Older chemo drugs cost less but require patients to use a steroid to prevent allergic reactions that might interfere with the immunotherapy. Abraxane was chosen because it avoids the need for a steroid, said one study leader, Dr. Sylvia Adams of NYU Langone Health.

The study was sponsored by Roche and many study leaders consult or work for the company or own stock in it. (VOA)